EUVIMEDEUVIMED entdecken
Multizentrische StudieKohortenstudie

Metabolic Complications After Initiating BIC/FTC/TAF Versus DTG + 3TC in Antiretroviral-therapy-naive Adults With HIV: A Multicenter Prospective Cohort Study

Alejandro G García-Ruiz de Morales iD, Miguel Suárez Robles, María Jesús Pérez-Elías, Eugènia Negredo, José Alcamí, Carmen Elena Gómez Rodríguez, Patricia González-Ruano, Miguel Alberto de Zárraga Fernández, Carlos Dueñas Gutiérrez, Santiago Moreno Guillén, Javier Martínez-Sanz iD

Clinical Infectious Diseases · 16.09.2025 · 81 (2) · 263-270

DOI: 10.1093/cid/ciae645 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Clinical Infectious Diseases, online erschienen am 28.03.2025. Verfasst von Alejandro G García-Ruiz de Morales und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Infectious Diseases, Hospital Universitario Ramón y Cajal, IRYCIS, Madrid, Spain. Hauptthemen laut MEDLINE: HIV Infections, Lamivudine, Anti-HIV Agents, Tenofovir. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 36 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Although antiretroviral therapy (ART) has become less toxic over time, its long-term adverse effects remain a concern. In ART-naive people, tenofovir alafenamide (TAF) is frequently prescribed to reduce the toxicity of tenofovir disoproxil fumarate (TDF). However, the metabolic impact of TAF remains a concern. This study aimed to evaluate the metabolic effects of TAF in ART-naive participants.

Methods

We analyzed data from the Cohort of the Spanish HIV Research Network (CoRIS). We included ART-naive participants who initiated either bictegravir/emtricitabine/TAF (BIC/FTC/TAF) or dolutegravir + lamivudine (DTG+ 3TC), matched by propensity score, after excluding those with hepatitis B. We compared changes in weight, metabolic biomarkers, and the incidence of metabolism-related clinical events over 96 weeks.

Results

In total, 340 participants were matched in each group. The median age was 34 years, 95% were male, and 62% were from Western Europe. The mean weight gain was 1.4 kg (95% confidence interval [CI]: 1.1, 1.8) after 96 weeks, with no significant differences between the BIC/FTC/TAF and DTG + 3TC groups. Changes in body mass index, lipid levels, hepatic steatosis index, and incidence of clinical events (hypertension, diabetes mellitus, dyslipidemia, and liver steatosis) were also similar between the groups.

Conclusions

In this nationwide cohort of ART-naive individuals, initiation of BIC/FTC/TAF or DTG + 3TC resulted in similar modest increases in weight and lipid levels after 96 weeks, with no significant differences in metabolic outcomes or clinical events. These findings suggest that the metabolic profile of TAF should not be a deciding factor when choosing between 2- and 3-drug ART regimens.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HIV InfectionsLamivudineAnti-HIV AgentsTenofovirAdenineMetabolic DiseasesHumansMaleFemaleAdultProspective StudiesEmtricitabinePiperazinesHeterocyclic Compounds, 3-RingPyridonesHeterocyclic Compounds, 4 or More RingsOxazinesAlanineWeight GainMiddle AgedSpainAmidesDolutegravir

Stichwörter der Autor:innen

HIVmetabolic eventsnaivetenofovir alafenamideweight gain

Substanzen

LamivudineAnti-HIV AgentsTenofovirEmtricitabinePiperazinesHeterocyclic Compounds, 3-RingPyridonesAdenineHeterocyclic Compounds, 4 or More RingsOxazines

Autor:innen und Institutionen

  • Department of Infectious Diseases, Hospital Universitario Ramón y Cajal, IRYCIS, Madrid, Spain.
  • CIBER de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Madrid, Spain.
  • Department of Medicine, University of Alcalá, Alcalá de Henares, Madrid, Spain.
  • Lluita contra les Infeccions, Hospital Universitari Germans Trias i Pujol, Badalona, Spain.
  • Universitat Autònoma de Barcelona, Barcelona, Spain.
  • Department of Medicine, Universitat de Vic-Universitat Central de Catalunya, Vic, Spain.

ORCID-Profile: Alejandro G García-Ruiz de Morales, Javier Martínez-Sanz

Zitieren

APA

García-Ruiz de Morales, A. G., Suárez Robles, M., Pérez-Elías, M. J., Negredo, E., Alcamí, J., Gómez Rodríguez, C. E., González-Ruano, P., de Zárraga Fernández, M. A., Dueñas Gutiérrez, C., Moreno Guillén, S., & Martínez-Sanz, J. (2025). Metabolic Complications After Initiating BIC/FTC/TAF Versus DTG + 3TC in Antiretroviral-therapy-naive Adults With HIV: A Multicenter Prospective Cohort Study. Clinical Infectious Diseases, 81(2), 263-270. https://doi.org/10.1093/cid/ciae645

Vancouver

García-Ruiz de Morales AG, Suárez Robles M, Pérez-Elías MJ, Negredo E, Alcamí J, Gómez Rodríguez CE, et al. Metabolic Complications After Initiating BIC/FTC/TAF Versus DTG + 3TC in Antiretroviral-therapy-naive Adults With HIV: A Multicenter Prospective Cohort Study. Clinical Infectious Diseases. 2025;81(2):263-270. doi:10.1093/cid/ciae645

BibTeX
@article{GarcaRuizdeMorales2025,
  author = {García-Ruiz de Morales, Alejandro G and Suárez Robles, Miguel and Pérez-Elías, María Jesús and Negredo, Eugènia and Alcamí, José and Gómez Rodríguez, Carmen Elena and González-Ruano, Patricia and de Zárraga Fernández, Miguel Alberto and Dueñas Gutiérrez, Carlos and Moreno Guillén, Santiago and Martínez-Sanz, Javier},
  title = {Metabolic Complications After Initiating BIC/FTC/TAF Versus DTG + 3TC in Antiretroviral-therapy-naive Adults With HIV: A Multicenter Prospective Cohort Study},
  journal = {Clinical Infectious Diseases},
  year = {2025},
  volume = {81},
  number = {2},
  pages = {263--270},
  doi = {10.1093/cid/ciae645}
}
Kostenlos starten →